Centers | ||
Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Therapeutic Accelerator Program (TAP) | EU-OPENSCREEN |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Test |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Partnerships |
Events |
Jobs |
Eisiai Partners with Johns Hopkins Brain Science InstituteEisiai Partners with Johns Hopkins Brain Science Institute ("BSi") an institute which is part of Johns Hopkins University to develop new drugs for neurological diseases. Under this joint collaboration, BSi will provide validated targets to Eisai... View all Janssen Pharmaceuticals and Johns Hopkins To Develop New Therapies to Treat Neurological DiseasesJanssen Pharmaceuticals (Formerly OMJPI) a Johnson and Johnson entity has entered into collaboration agreement with Johns Hopkins Brain Science Institute ("BSi") at Johns Hopkins University. Janssen will be working with Johns Hopkins researchers... View all Yale to Partner with Gilead to Further Cancer ResearchYale and Gilead have entered into a multi-year research collaboration to develop new treatments against cancer. Gilead will provide $40million in funding for research and other infrastructure support for the initial four years. The agreement can... View all |
No EVENTS for listing |
No Job Posts |


